Another example is cancer cell‐derived EVs bearing programmed death ligand‐1 (PD‐L1), which can lead to cancer immune evasion via inhibition of T cell function by binding to programmed cell death protein‐1 (PD1).[84, 136, 137, 138] Apart from their immunomodulatory function, Wnt protein‐bearing EVs can induce Wnt signaling activity in recipient cells.[124, 139] This property indicates that EVs could be promising candidates for developing immunomodulatory therapeutics and antitumor vaccines. Here, PDCD1 is linked to cancer.